Details of the Drug

General Information of Drug (ID: DM4OKXI)

Drug Name
Benzotetronic acid
Synonyms
Coumarin, 4-hydroxy-; X954ZLL2RD; 1076-38-6; 2-Hydroxychromone; 2-hydroxychromen-4-one; 2H-1-BENZOPYRAN-2-ONE, 4-HYDROXY-; 4-Coumarinol; 4-Hydroxycoumarin; 4-HYDROXY-1-BENZOPYRAN-2-ONE; 4-Hydroxy-2H-1-benzopyran-2-one; 4-Hydroxy-2H-chromen-2-one; 4-Hydroxy-chromen-2-one; 4-Hydroxycoumarin, 98%; 4-Hydroxycoumarine; 4-hydroxy-2-chromenone; 4-hydroxy-coumarin; 4-hydroxychromen-2-one; 4H-1-Benzopyran-4-one, 2-hydroxy-; AI3-52393; BRN 0129768; CHEMBL301141; EINECS 214-060-2; MFCD00006856; NSC 11889; UNII-X954ZLL2RD
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 162.14
Logarithm of the Partition Coefficient (xlogp) 1.3
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C9H6O3
IUPAC Name
4-hydroxychromen-2-one
Canonical SMILES
C1=CC=C2C(=C1)C(=CC(=O)O2)O
InChI
InChI=1S/C9H6O3/c10-7-5-9(11)12-8-4-2-1-3-6(7)8/h1-5,10H
InChIKey
VXIXUWQIVKSKSA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
54682930
ChEBI ID
CHEMBL40070
CAS Number
1076-38-6
UNII
X954ZLL2RD
DrugBank ID
DB03410
INTEDE ID
DR0012
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Vitamin K epoxide reductase complex subunit 1 OTOJNJRD VKOR1_HUMAN Gene/Protein Processing [2]
Vitamin K epoxide reductase complex subunit 1-like protein 1 OT7QSEWT VKORL_HUMAN Gene/Protein Processing [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol. 1995 Jan;39(1):71-6.
2 VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. Blood Adv. 2018 Mar 27;2(6):691-702.